PHARMACEUTICAL COMPOSITION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME Russian patent published in 2022 - IPC A61K31/569 A61K9/48 A61K47/14 A61P25/28 A61P1/16 

FIELD: pharmaceutics.

SUBSTANCE: invention relates to an oral pharmaceutical composition in the form of a lipid solution, including 3α-ethynyl-3β-hydroxyandrostan-17-one oxime and a carrier. The carrier contains 45-100% of composite monoester, which is monoglyceride or propylene glycol monoester, if necessary, up to 51% of composite diester, which is diglyceride or propylene glycol diester, and, if necessary, up to 10% of composite triester, which is triglyceride. In this case, composite monoester, composite diester (if present) and/or composite triester (if present) contains fatty acid selected from caprylic acid (C8) in amount of 50-90%; capric acid (C10) in amount of 10-50%; capronic acid (C6) in amount of up to 3%; lauric acid (C12) in amount of up to 100%; palmitic acid (C16) in amount of up to 12%; myristic acid (C14) in amount of up to 3%; stearic acid (C18) in amount of up to 6%; oleic acid (C18:1) in amount of up to 100%, and linoleic acid (C18:2) in amount of up to 35%. 3α-ethynyl-3β-hydroxyandrostan-17-one oxime is 0.1-10 wt.% of the total weight of the composition. The invention also relates to a method for the production of the specified composition by heating of the carrier and addition of an active agent until complete dissolution.

EFFECT: invention provides improved delivery of an active agent, its bioavailability, and therapeutic effect in vivo.

23 cl, 3 dwg, 2 tbl, 10 ex